How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies

J Clin Oncol. 2021 Feb 10;39(5):456-466. doi: 10.1200/JCO.20.01616. Epub 2021 Jan 12.

Authors

Patrick M Reagan¹, Sattva S Neelapu²

Affiliations

¹ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
² Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

PMID: 33434058
DOI: 10.1200/JCO.20.01616

No abstract available

Publication types

Review

MeSH terms

Animals
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
Immunotherapy, Adoptive / adverse effects*
Immunotherapy, Adoptive / methods*
Neoplasms / immunology
Neoplasms / therapy
Receptors, Chimeric Antigen / immunology

Substances

Receptors, Chimeric Antigen